Drug maker Trevi Therapeutics (TRVI) is climbing 4.5% after investment bank Stifel raised its price target on the name to $12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback